Love Hemp Group Plc

Love Hemp Group Plc is a private equity and venture capital firm specializing in acquisition, early stage and mature companies. It may invest as debt or equity, in either quoted or unquoted securities, and made by direct acquisition of an interest in companies, partnerships or joint ventures, or direct interests in projects, or by way of licensing arrangements. It typically invests in companies operating in the Cannabidiol (CBD) wellness and medicinal cannabis, hemp including the industrial hemp with focus on therapeutic cannabis derivatives including nutraceuticals, dietary supplements and cosmetic products. The firm also seeks to invest in the cultivation of cannabis and hemp, premium quality, feel good CBD oils, edibles, cosmetics, capsules, the manufacture and distribution of medicinal cannabis, hemp and CBD products, pharmacology commercialization of medicinal cannabis, hemp and CBD, professional prescription by practitioners and after care as it relates to medicinal cannabis, statistical management, laboratory testing and compliance in respect of medicinal cannabis, hemp and CBD sectors, and the development of CBD within the wellness sector including retail products such as patches, topical ointments, tinctures, beverages, powdered supplements as well as vaping capsules, e-liquids and oils. The firm typically invests in Europe, United Kingdom, Germany, Netherlands, North America, Australia, Japan, Thailand, Canada, Africa and South America, Israel and Asia. The firm will hold investments for the medium to long term, although where opportunities exist for shorter-term investments, it may undertake such investments. The firm typically acquire control in certain situations, although it may also consider acquiring non-controlling positions. The firm seeks to take majority stake. Love Hemp Group Plc was founded on 30th January 2019 and is based in London, United Kingdom with additional offices in London, United Kingdom.

Love Hemp Group Plc trades as WRHLF on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Love Hemp Group Plc can be compared against peers such as Advantis Corp., Black Bird Biotech, Inc., CannLabs, Inc., Parallel Industries Inc., The Greater Cannabis Company, Inc., Green Rain Energy Holdings Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $82,915, beta of 1.78, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

WRHLF currently shows total debt of N/A and beta of 1.78. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.worldhighlife.uk

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.